BioMed Research International / 2016 / Article / Tab 1 / Review Article
The Role of 18 F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis Table 1 Characteristics of included studies for detecting pathologic response to neoadjuvant chemotherapy.
Author County Year Study design Number of patients Mean age Type of NAC Cycles of NAC Evaluation time Endpoint pCR/npCR Evaluation index Sen.
Pengel et al. [23 ] Netherlands 2014 Pro. 93 47.8 Trastuzumab-based regimen 3 or 6 B/A (1 or 3 cycles) pCR 43/50 MRI 0.465
Kim et al. [22 ] Korea 2014 Retro. 59 46.6 NR 3 or 6 B/A (3 or 6 cycles) Miller and Payne system 34/22 MRI 0.912
Tateishi et al. [21 ] Japan 2012 Retro. 142 57 5-Fluorouracil, epirubicin, cyclophosphamide, and so forth 4 B/A (2 cycles) pCR 24/118 MRI 0.50
Park et al. [20 ] Korea 2011 Retro. 32 45 Doxorubicin and docetaxel 3 or 6 B/A (18–22 days) pCR 8/24 MRI 0.625
Choi et al. [19 ] Korea 2010 Pro. 41 45.1 Adriamycin and cyclophosphamide or docetaxel 3 or 8 B/A (3 or 8 cycles) pCR 7/34 MRI 0.714
Chen et al. [18 ] USA 2004 Pro. 15 44 Anthracycline-based regimen NR B/A pCR 10/6 MRI 0.333
NR: not reported.
